Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.

Saxena M, Bhardwaj N.

Curr Opin Immunol. 2017 Aug;47:35-43. doi: 10.1016/j.coi.2017.06.003. Epub 2017 Jul 18. Review.

2.

Dendritic cell-based immunotherapy: a basic review and recent advances.

Constantino J, Gomes C, Falcão A, Neves BM, Cruz MT.

Immunol Res. 2017 Aug;65(4):798-810. doi: 10.1007/s12026-017-8931-1. Review.

PMID:
28660480
3.

Dendritic cells and immunotherapy for cancer.

Chang DH, Dhodapkar MV.

Int J Hematol. 2003 Jun;77(5):439-43. Review.

PMID:
12841381
4.

Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.

da Cunha A, Antoniazi Michelin M, Cândido Murta EF.

Immunol Lett. 2016 Sep;177:25-37. doi: 10.1016/j.imlet.2016.07.009. Epub 2016 Jul 14.

PMID:
27423825
5.

Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.

Hennies CM, Reboulet RA, Garcia Z, Nierkens S, Wolkers MC, Janssen EM.

Clin Exp Immunol. 2011 Mar;163(3):381-91. doi: 10.1111/j.1365-2249.2010.04305.x. Epub 2011 Jan 14.

6.

Dendritic cells from bench to bedside and back.

Adema GJ.

Immunol Lett. 2009 Feb 21;122(2):128-30. doi: 10.1016/j.imlet.2008.11.017. Epub 2008 Dec 31. Review.

PMID:
19121337
7.
8.

Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.

Ohshio Y, Teramoto K, Hanaoka J, Tezuka N, Itoh Y, Asai T, Daigo Y, Ogasawara K.

Cancer Sci. 2015 Feb;106(2):134-42. doi: 10.1111/cas.12584. Epub 2015 Jan 16.

9.
10.

Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.

Laurell A, Lönnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren AC, Andersson B, Adamson L, Kiessling R, Karlsson-Parra A.

J Immunother Cancer. 2017 Jun 20;5:52. doi: 10.1186/s40425-017-0255-0. eCollection 2017.

11.

The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.

Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM.

J Immunol. 2006 Jan 1;176(1):157-64.

12.

Cancer immunotherapy: moving forward with peptide T cell vaccines.

Kumai T, Fan A, Harabuchi Y, Celis E.

Curr Opin Immunol. 2017 Aug;47:57-63. doi: 10.1016/j.coi.2017.07.003. Epub 2017 Jul 19. Review.

13.

SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Sharma RK, Yolcu ES, Shirwan H.

Expert Rev Vaccines. 2014 Mar;13(3):387-98. doi: 10.1586/14760584.2014.880340. Review.

14.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
15.

Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.

Dobrovolskienė N, Pašukonienė V, Darinskas A, Kraśko JA, Žilionytė K, Mlynska A, Gudlevičienė Ž, Mišeikytė-Kaubrienė E, Schijns V, Lubitz W, Kudela P, Strioga M.

Vaccine. 2018 Jul 5;36(29):4171-4180. doi: 10.1016/j.vaccine.2018.06.016. Epub 2018 Jun 9.

PMID:
29895501
16.

Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.

Walsh MP, Duncan B, Larabee S, Krauss A, Davis JP, Cui Y, Kim SY, Guimond M, Bachovchin W, Fry TJ.

PLoS One. 2013;8(3):e58860. doi: 10.1371/journal.pone.0058860. Epub 2013 Mar 12.

17.

Dendritic Cells and Cancer Immunity.

Gardner A, Ruffell B.

Trends Immunol. 2016 Dec;37(12):855-865. doi: 10.1016/j.it.2016.09.006. Epub 2016 Oct 25. Review.

18.

Dendritic-cell-based therapeutic cancer vaccines.

Palucka K, Banchereau J.

Immunity. 2013 Jul 25;39(1):38-48. doi: 10.1016/j.immuni.2013.07.004. Review.

19.

Cancer vaccines for established cancer: how to make them better?

Andrews DM, Maraskovsky E, Smyth MJ.

Immunol Rev. 2008 Apr;222:242-55. doi: 10.1111/j.1600-065X.2008.00612.x. Review.

PMID:
18364006
20.

Vaccines targeting helper T cells for cancer immunotherapy.

Melssen M, Slingluff CL Jr.

Curr Opin Immunol. 2017 Aug;47:85-92. doi: 10.1016/j.coi.2017.07.004. Epub 2017 Jul 26. Review.

Supplemental Content

Support Center